RE: It works21 May 2024 11:35
A reminder from the data RNS:
AVA6000 delivers high concentrations of doxorubicin to the tumor microenvironment ("TME") relative to plasma, resulting in significant antitumor activity in patients whose tumors have over-expression of Fibroblast Activation Protein ("FAP")
FAP-enabled release of doxorubicin directly in the TME results in a favorable safety profile, tumor responses and a wider therapeutic index compared to standard doxorubicin dosing .
Scientific data, imagine that, not just made up tripe from the three amigos.